Biotech Values

[ghmm]

HCV Proteases/VRTX:

Sorry if I missed it posted here before but I was thinking a bit more behind another reason why VRTX is interested in monetizing the milestone payment is a less then healthy relationship with J&J.

The (other) collaboration J&J has for a protease inhibitor with Medivir seems to be progressing quite well. While Telaprevir may certainly have a head start TMC435 seems quite promising. If TMC435 doesn't encounter strong safety concern and continues to show very high potency from a competitive and economic standpoint wouldn't it make sense for J&J to promote it instead?